Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
Key Highlights
- ➤Molteni receives exclusive EXPAREL commercialization rights across licensed EU and UK territories
- ➤Pacira receives undisclosed upfront payment, supply price, and future sales royalties
- ➤EXPAREL launches sequentially in Italy, Germany, Austria, and Poland, beginning in 2027
- ➤Molteni plans to pursue EXPAREL approval in Switzerland
- ➤Pacira grants inducement awards covering 3,600 options and 4,200 restricted stock units
Expert Statements
Frank D. Lee, Chief executive officer of Pacira BioSciences
“We are excited to announce another strategic partnership that advances our 5x30 growth strategy and reinforces our commitment to expanding patient access to best-practice opioid-sparing postsurgical pain management”
Frank D. Lee, Chief executive officer of Pacira BioSciences
“With Molteni Farmaceutici’s longstanding leadership in pain management and extensive distribution network across Europe, they are ideally positioned to unlock EXPAREL’s full potential in key European markets.”
Gianluca Corbinelli, Chief executive officer at Molteni Farmaceutici
“This agreement is highly complementary with Molteni’s strategic priorities, and represents an important step in Molteni’s international growth and expansion strategy, while adding an innovative and differentiated medicine to our portfolio.”
Gianluca Corbinelli, Chief executive officer at Molteni Farmaceutici
“We believe EXPAREL represents a compelling opportunity to address the significant unmet need for effective postsurgical pain management across Europe”
Gianluca Corbinelli, Chief executive officer at Molteni Farmaceutici
“We look forward to bringing this important treatment to more patients and healthcare providers across the region.”
– Expands patient access to opioid-sparing pain control and advances 5x30 strategy –
BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic partnership with Molteni Farmaceutici to expand access to opioid-sparing postsurgical pain management across European markets. Through this partnership, Molteni Farmaceutici will receive exclusive rights to distribute and commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira’s long-acting, local analgesic for postsurgical pain management, within the licensed territories.
Get started
Create a free account to read the full story.